NCT06163898 2026-04-21
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1 Terminated
Clinical Trials
13 trialsNCT01081028 2026-04-13
Connect® MM- The Multiple Myeloma Disease Registry
Celgene
Terminated
NCT02681302 2026-04-03
CPIT001
Hackensack Meridian Health
Phase 1/2 Terminated
NCT04318327 2026-04-01
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Novartis
Phase 1 Terminated
NCT01453088 2026-03-24
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
Phase 2 Terminated
NCT06068400 2026-03-17
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd
Phase NA Terminated
NCT04827563 2026-03-04
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
University of Chicago
Terminated
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03622775 2026-02-10
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03374085 2026-02-09
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene
Phase 1/2 Terminated
NCT05590377 2026-01-30
iinnovate-3
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT03215030 2026-01-29
iinnovate-1
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated